Basic Information
| LncRNA/CircRNA Name | MIR17HG |
| Synonyms | MIR17HG, C13orf25, FGLDS2, LINC00048, MIHG1, MIRH1, MIRHG1, NCRNA00048, miR-17-92 |
| Region | GRCh38_13:91347820-91354579 |
| Ensemble | ENSG00000215417 |
| Refseq | NR_027349 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | Microarray, qPCR etc. |
| Sample | prostate cancer tissues, cell lines (LNCaP) |
| Expression Pattern | up-regulated |
| Function Description | Five lncRNAs, RP1-4514.2, SUZ12P1, SNHG5, LINC01138, and SNHG1, were down-regulated under DHT treatment. Five lncRNAs, KLKP1, LINC00969, LINC-PINT, TUG1 and MIR17HG, were up-regulated under DHT treatment. Notably, RP1-4514.2 and LINC01138 were induced and KLKP1 was reduced over 2 fold after AR silenced, suggesting the involvement of AR in androgen-mediated regulation of these lncRNAs expressions. |
| Pubmed ID | 27556357 |
| Year | 2016 |
| Title | Identification of androgen-responsive lncRNAs as diagnostic and prognostic markers for prostate cancer. |
External Links
| Links for MIR17HG | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |